FLGT at a glance
Fulgent Genetics, Inc. (FLGT, SEC CIK 1674930) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on July 30, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Fulgent Genetics, Inc. (FLGT) reported revenue of $322.7 million (up 13.8% from FY2024) and a net loss of $60.5 million.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Fulgent Genetics, Inc. (FLGT) shares worth $167.5 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Gao Hanlin on September 2, 2026 of 1,673 shares at $19.66 per share.
- In the last 90 days, FLGT insiders reported 0 open-market purchases ($0) and 4 open-market sales ($117K) on Form 4, a net sale of $117K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $322.7M
- +13.8% vs prior year
- Insiders · 90 days
- 0 buys · 4 sells
- Net −$117K
- 13F holders
- 25 funds
- $167.5M · −2 vs prior quarter
- Latest 8-K
- Jul 30, 2026
- Item 2.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $85.4M, up 4% YoY from $81.8M, driven by anatomic pathology growth
- Anatomic pathology $37.5M, up 33%; precision diagnostics $41.5M, down 13%
- Gross margin 30% vs 42% YoY; operating loss $36.1M vs $19.7M
- Cash, restricted cash, and marketable securities $551.5M vs $705.5M at December 31, 2025
- Bako Acquisition funded from existing cash; largest customer revenue expected to continue declining in 2026
Risk Factors
- No material risk-factor changes from the 2025 Annual Report
- Regulatory and compliance risks carried forward without quarterly updates
- Competitive and operational risks remain those identified in the 2025 Annual Report
- Stock-repurchase liquidity allocation: $75.8 million remained available at June 30, 2026
AI summary of the FLGT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 fiscal 2026 results for quarter ended June 30, 2026
- Press release issued July 30, 2026
Item 7.01: Regulation FD Disclosure
- Updated investor presentation released July 30, 2026, providing refreshed business information for the investment community
- Presentation available through Fulgent Genetics’ investor-relations website and furnished as Exhibit 99.2
Item EX-99.1: Item EX-99.1
- Q2 revenue $85.4M, up 20.1% sequentially, but GAAP gross margin fell to 30.1% from 42.1% year over year
- GAAP loss widened to $29.5M, or $1.05 per share, versus $19.0M, or $0.62, in Q2 2025
Item 8.01: Other Events
- Fulgent presenting updated FID-007 plus cetuximab data in recurrent/metastatic HNSCC at ASCO 2026
- Rapid Oral Abstract Session elevates visibility for FID-007’s oncology development program
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Stockholders approved the 2026 Equity Incentive Plan on May 14, 2026, replacing the Prior Plan
- 2026 Plan authorizes 2,000,000 new common shares for employee equity awards
Item 5.07: Submission of Matters to a Vote of Security Holders
- 83% quorum: 24,578,996 of 29,747,420 eligible shares represented
- All four director nominees elected through 2027; Ming Hsieh strongest support at 21,979,668 votes
AI summaries of FLGT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for FLGT
Don't miss the next FLGT filing
- Alerts as it files. A push when FLGT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut FLGT, by share count.
- Ask anything. An AI agent that reads every FLGT filing and answers with sources.
FLGT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Gao Hanlin | Sell | Sep 2, 2026 | 1,673 | $19.66 |
| Xie Jian | Sell | Sep 2, 2026 | 2,127 | $19.66 |
| Kim Paul | F | Sep 1, 2026 | 2,087 | $19.59 |
| Hsieh Ming | F | Sep 1, 2026 | 4,392 | $19.59 |
| Xie Jian | Sell | Aug 27, 2026 | 1,193 | $19.91 |
| Gao Hanlin | Sell | Aug 27, 2026 | 939 | $19.91 |
| Kim Paul | F | Aug 26, 2026 | 1,168 | $19.81 |
| Hsieh Ming | F | Aug 26, 2026 | 2,949 | $19.81 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $283.5M | $322.7M |
| Gross Profit | $104.5M | $107.2M | $130.9M |
| Operating Income | -$195.5M | -$73.9M | -$91.1M |
| Net Income | -$167.8M | -$42.7M | -$60.5M |
| Gross Margin | - | 37.8% | 40.6% |
| Op. Margin | - | -26.1% | -28.2% |
| Net Margin | - | -15.1% | -18.8% |
| Balance Sheet | |||
| Total Assets | $1.2B | $1.2B | $1.2B |
| Equity | - | $1.1B | $1.1B |
| ROE | - | -3.8% | -5.4% |
| Cash Flow | |||
| Operating CF | - | $21.1M | -$101.6M |
| CapEx | - | $40.3M | $22.6M |
Source: XBRL data in Fulgent Genetics, Inc. (FLGT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate FLGT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $167.5M |
| Q1 2026 | 27 | $135.9M |
| Q4 2025 | 24 | $260.8M |
| Q3 2025 | 23 | $239.1M |
| Q2 2025 | 24 | $182.3M |
| Q1 2025 | 22 | $133.0M |
| Q4 2024 | 20 | $144.6M |
| Q3 2024 | 18 | $124.8M |
- JPMorgan Chase & Co+296.2K (+64%)
- Citadel Advisors LLC+121.2K (+229%)
- Ameriprise Financial+106.7K (+19%)
- Two Sigma Investments+78.8K (+24%)
- Bank of America Corp+55.0K (+46%)
- BlackRock−487.9K (-18%)
- D.E. Shaw & Co−194.8K (-40%)
- Vanguard Capital Management LLC−90.7K (-10%)
- Wells Fargo & Co−87.8K (-60%)
- Millennium Management−80.9K (-20%)
- Renaissance Technologies LLC−18.0K
- Franklin Resources−13.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 183 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
FLGT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 27, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 8-K | May 14, 2026 | - | Analysis |
Related Health Care companies
- CDNA · CareDx, Inc.Services-Medical Laboratories
- CSTL · CASTLE BIOSCIENCES INCServices-Medical Laboratories
- CELC · Celcuity Inc.Services-Medical Laboratories
- FTRE · Fortrea Holdings Inc.Services-Medical Laboratories
- GRAL · GRAIL, Inc.Services-Medical Laboratories
- GH · Guardant Health, Inc.Services-Medical Laboratories
- LH · LabcorpServices-Medical Laboratories
- NTRA · Natera IncServices-Medical Laboratories
FLGT SEC filings: frequently asked questions
Are FLGT insiders buying or selling?
In the last 90 days, Fulgent Genetics, Inc. (FLGT) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $117,132 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold FLGT stock?
As of June 30, 2026, the largest Fulgent Genetics, Inc. (FLGT) holders among the 13F filers tracked by SignalX were BlackRock ($46.9 million), Vanguard Capital Management LLC ($16.2 million), JPMorgan Chase & Co ($15.5 million), Ameriprise Financial ($13.8 million), Dimensional Fund Advisors ($12.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was FLGT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Fulgent Genetics, Inc. (FLGT) reported revenue of $322.7 million (up 13.8% from FY2024) and a net loss of $60.5 million. The figures come from the XBRL data in the 10-K.
What did FLGT report in its latest 8-K?
Fulgent Genetics, Inc. (FLGT) filed an 8-K on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q2 fiscal 2026 results for quarter ended June 30, 2026.
What are the latest FLGT SEC filings?
Fulgent Genetics, Inc. (FLGT) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on July 30, 2026 and a Form 4 insider filing on September 3, 2026.
What is FLGT's SEC CIK number?
Fulgent Genetics, Inc. (FLGT)'s SEC Central Index Key (CIK) is 1674930. EDGAR lists every FLGT filing under that number.
Ask anything about FLGT
The research agent reads FLGT's filings, financials, insider trades and 13F holders, then answers with sources.